CTRI/2022/01/039292招募中未知
A randomized, double-blind, placebo controlled, monocentric study to evaluate the efficacy of the LactoSporin�® on age related changes in the skin of healthy female participants
SamiSabinsa Group Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Ã¢â?¬Â¢Female adult participants in general good health as determined from a recent medical history general physical examination, dermatological assessment.
- •Ã¢â?¬Â¢Participants in the age group of 35-65years (both ages inclusive).
- •Ã¢â?¬Â¢Subject with Fitzpatrick skin types III to V
- •Ã¢â?¬Â¢Participants with mild to moderate fine lines and wrinkles in periorbital area (Crowââ?¬•s feet-under eye) & forehead (Refer annexure I for photo-numerical scale)
- •Ã¢â?¬Â¢Participants free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the f ace.
- •Ã¢â?¬Â¢Participants who agree not to use any other product/treatment/home remedy/soap bar on their face during the study period other than the test product.
- •Ã¢â?¬Â¢Participants who agree not to carry out bleaching or any other procedures including facial etc. on face during the study period.
- •Ã¢â?¬Â¢Participants who agree not to expose to excessive sun light. (Sun exposure not more than half an hour daily and during that time use of umbrella to cover face).
- •Ã¢â?¬Â¢Participants who agree to remove all jewellery on/around face (e.g., necklace, earrings, if possible, nose ring), during VISIA imaging.
- •Ã¢â?¬Â¢Participants willing to give a voluntary written informed consent, photography release and agree to come for regular follow up.
- •Ã¢â?¬Â¢Participants willing to abide by and comply with the study protocol.
- •Ã¢â?¬Â¢Participants who have not participated in a similar investigation in past four weeks.
- •Ã¢â?¬Â¢Participants who are willing not to participate in any other clinical study during participation in the current study.
排除标准
- •Ã¢â?¬Â¢Participant with any other signs of significant local irritation or skin disease.
- •Ã¢â?¬Â¢Participant currently taking any medication, which the Investigator believes may influence the interpretation of the data.
- •Ã¢â?¬Â¢Participant having chronic illness or had major surgery in the last year.
- •Ã¢â?¬Â¢Participants undergoing any treatment of any skin condition on their face/forearm.
- •Ã¢â?¬Â¢Participants not willing to discontinue other topical facial products.
- •Ã¢â?¬Â¢Participant allergic or sensitive to bar cleansing products, creams/lotions, or anything else.
- •Ã¢â?¬Â¢Pregnant or nursing participant.
- •Ã¢â?¬Â¢Participants taking medication including food supplements.
研究者
相似试验
尚未招募
3 期
In this study the effectiveness and safety of Olepent as an anti ageing cream will be evaluated in comparison to an inert cream in healthy female volunteers.CTRI/2019/09/021246Sami Labs Limited
进行中（未招募）
1 期
Effects of mepolizumab compared to placebo on airway physiology in patients with eosinophilic asthma: MEMORY studysevere eosinophilic asthmaMedDRA version: 18.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855EUCTR2015-001868-19-DEniversity medical center of Johannes Gutenberg University Mainz
已完成
不适用
A randomized, double-blind, placebo- controlled, multi-center, parallel study concerning the efficacy of repetitive transcranial magnetic stimulation over the supplementary motor area in treatment of motor and non- motor symptoms in Parkinson's diseases diseaseParkinson's diseaseJPRN-UMIN000001576Department of neurology, Fukushima medical university150
进行中（未招募）
1 期
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people who already have vascular disease.Atherosclerotic cardiovascular disease (ASCVD)MedDRA version: 21.1Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 100000004866EUCTR2021-002006-27-FRovartis Pharma AG15,000
进行中（未招募）
1 期
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people who already have vascular disease.Atherosclerotic cardiovascular disease (ASCVD)MedDRA version: 26.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersEUCTR2021-002006-27-DKovartis Pharma AG16,500